

Phone: 732-390-7750 Fax: 844-683-2244 *AsteraCancerCare.org*

PATIENT REFERRAL FORM

RHEUMATOLOGY

Patient Name:		_ Pt. DOB:	_/	_/
Last First	Middle			
Patient Address:				
Patient City:		Pt. Zip:		
Patient Phone:()		Pt. Height: _		in.
DX:		Pt. Weight: _		lbs.
Patient Allergies:				
Insurance:		ID#:		
Referred by:	NPI#:			
Office Contact (Required):	Offi	ce Ph: ()		
	Offi	ce Fax: ()		
Office Administrator (Required):	Administra	tor Ph: ()		
Astera Infusion Services scheduling location request:	■Brick ■Bridgewate	er D East Brunswick		
■Edison ■Jersey City ■Monroe ■Robbinsville	□Rutherford □Som	erset Toms River	ŕ	
Required Items/Infusion Process:				
\square Valid/signed written prescription including na	ime of medication, ex	act dosage, and dir	ections	
(prescription only valid for 6 months, including	ng refills)			
☐ Copy of current insurance card				
☐ Recent MD consultation notes: relevant disease	se being treated must	be mentioned in re	port	
☐ Allergies and current medication list				
☐ Current labs required for specific medication, a	as noted on the follow	ing page(s) of this fo	orm	
Has the patient initiated treatment at your office	? □ Y	es	No	
☐ If any future lab tests are needed, please provi	de patient with a pres	cription, and have p	oatient k	oring on
day of treatment. Results will be sent to referring	g physician.			
Please note:				

- 1. A Letter of Medical Necessity is required for all patients receiving their initial infusion at Astera (letter must include diagnosis, previous treatments/response to treatments and be on letterhead with physician signature).
- 2. Benefit investigations, copay assistance and prior authorizations will be handled by the Astera precert staff if required by the payer. Right to auto-substitute biosimilars based on payer's preference. Detailed clinical notes providing supportive documentation are required for authorization requests which may take 3-5 business days depending on the payer and receipt of complete documentation from the referring office. The precert staff will update the referring doctor's office during this process and contact the patient to discuss cost and financial assistance options. For certain medications, patients will be required to register/enroll with the pharmaceutical company prior to rendered services and will receive a call from an Astera Financial Counselor to assist with this process.
- 3. A pretreatment education session will be provided by an Advanced Practice Provider.
- 4. Once the infusion is complete, a follow-up notice will be faxed to the to the referring provider.

Patient Name:				DOB:	/_	/			
	Last	First	Middle						
Please check the box for medication requested, attach required documentation as noted below, and fax all documents to our office at 844.683.2244. Once all documentation is received, we will contact your patient to schedule an appointment. Thank you!									
Medication	Re	equired Current Lab	Results						
Note: Progress notes and labs must be completed within the previous 6 months for all new and renewed prescriptions.									
□ Actemra	CBC, Lipid Panel	, Liver Function, PPD	(prior to initiation)						
☐ Benlysta(IV)	None								
☐ Cimzia	CBC, Prior to init core antibody)	ciation – PPD and Hep	o B Serology (Hep B sur	rface antigen, H	lep B surfa	ace antibody and Hep B			
☐ Evenity	CMP, Dexa Scan ☐ Confirm pt. ha	•	troke within previous y	year					
□ Krystexxa	G6PD Deficience	y, Serum Uric Acid Le	vels, Confirm Oral Ura	te Lowering Ag	ent Discon	ntinued			

Prior to initiation – PPD and Hep B Serology (Hep B surface antigen, Hep B surface antibody and

CBC, Liver Function, Prior to initiation – PPD and Hep B Serology (Hep B surface antigen, Hep B

CBC, prior to initiation - Hep B Serology (Hep B surface antigen, Hep B surface antibody and

Up to date with all immunizations before treatment initiation and confirm no live or live

☐ Rituxan/Riabni/Truxima/Ruxience (CMS approved indications only - Biosimilar might be replaced if appropriate)

☐ Simponi Aria(IV) CBC, Liver Function, Prior to initiation — PPD and Hep B Serology (Hep B surface antigen,

4/16/25

☐ Vpriv

☐ Orencia(IV)

☐ Saphnelo

Hep B core antibody)

Hep B core antibody)

☐ Remicade/Inflectra (Biosimilar might be replaced if appropriate)

surface antibody and Hep B core antibody)

☐ Confirm No Vaccinations within 4 Weeks of Therapy

Hep B surface antibody and Hep B core antibody)

attenuated vaccines are given concurrently.

Gene Testing (GBA – Velaglucerase Alfa)